Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope
Portfolio Pulse from Vandana Singh
Alnylam Pharmaceuticals' KARDIA-1 Phase 2 study of zilebesiran, a drug for hypertension, has met its primary endpoint. The drug is being co-developed with Roche Holdings. The study showed a significant reduction in blood pressure and met key secondary endpoints. The results reaffirm the program's potential and could impact Ionis Pharmaceuticals, which is developing a similar therapeutic. Alnylam's shares are up 0.92%.
September 07, 2023 | 6:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alnylam's Phase 2 study of zilebesiran met its primary endpoint, potentially boosting the company's stock.
The positive results from the Phase 2 study of zilebesiran could increase investor confidence in Alnylam, potentially leading to a rise in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Roche Holdings is co-developing zilebesiran with Alnylam, which could have a positive impact on its stock.
As a co-developer of zilebesiran, Roche could also see a positive impact on its stock due to the successful results of the Phase 2 study.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
The success of zilebesiran could impact Ionis Pharmaceuticals, which is developing a similar therapeutic.
The success of zilebesiran could set a high benchmark for efficacy in the field, potentially impacting the development and reception of Ionis Pharmaceuticals' similar therapeutic.
CONFIDENCE 70
IMPORTANCE 70
RELEVANCE 60